Diagnosis and Treatment of Primary Tracheobronchial Tumors

ABSTRACT Background Primary tracheobronchial tumors (PTBTs) are rare but life‐threatening, accounting for approximately 0.2% of all respiratory neoplasms. Owing to their nonspecific clinical symptoms, PTBTs are often initially misdiagnosed as bronchial asthma or bronchitis in the early stages. In ad...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Shu, Yu‐jian Liu, Kai‐fu Zheng, Xi‐yang Tang, Meng‐chao Li, Yang Shen, Yu‐long Zhou, Wei‐guang Du, Nan Ma, Jin‐bo Zhao
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70893
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Primary tracheobronchial tumors (PTBTs) are rare but life‐threatening, accounting for approximately 0.2% of all respiratory neoplasms. Owing to their nonspecific clinical symptoms, PTBTs are often initially misdiagnosed as bronchial asthma or bronchitis in the early stages. In addition, standardized treatments for PTBTs are currently lacking. Aims This study aimed to provide a comprehensive review of this diagnostic challenge and treatment modalities of PTBTs. Methods Drawing on the latest literature and clinical guidelines, we carried out a comprehensive and systematic analysis of PTBTs, focusing on diagnostic modalities, and evidence‐based treatment options. Results and Conclusions Primary diagnostic methods for PTBTs include pulmonary function tests, chest radiography, computed tomography, and fiberoptic bronchoscopy. Computed tomography, and fiberoptic bronchoscopy may be the most valuable diagnostic tools for patients with PTBTs or those highly suspected of having PTBTs. Currently, there are no consensus guidelines for PTBTs, and surgery is the most effective method for treating PTBTs if the patients have indications for surgery. In addition, radiotherapy, chemotherapy and interventional therapy may be useful complementary treatments for inoperable patients. Immunotherapy may be a significant management strategy for PTBTs in the future. Further researches should concentrate on both the early identification and enhanced therapeutic management of these tumors to improve survival and diminish morbidity and mortality rates by investigating the optimal design of systematic therapy.
ISSN:2045-7634